Roivant Sciences Ltd
F:87S

Watchlist Manager
Roivant Sciences Ltd Logo
Roivant Sciences Ltd
F:87S
Watchlist
Price: 19.43 EUR 1.46%
Market Cap: 14.4B EUR

Net Margin

-2 157.4%
Current
Declining
by 3 576.5%
vs 3-y average of 1 419.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 157.4%
=
Net Income
$-374m
/
Revenue
$20.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 157.4%
=
Net Income
€-374m
/
Revenue
$20.3m

Peer Comparison

Country Company Market Cap Net
Margin
UK
Roivant Sciences Ltd
F:87S
13.2B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.6B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.9B USD
Loading...
No Stocks Found

Market Distribution

Lower than 99% of companies in United Kingdom
Percentile
1st
Based on 3 670 companies
1st percentile
-2 157.4%
Low
-188 120% — 0%
Typical Range
0% — 0.1%
High
0.1% — 10 443.9%
Distribution Statistics
United Kingdom
Min -188 120%
30th Percentile 0%
Median 0%
70th Percentile 0.1%
Max 10 443.9%

Roivant Sciences Ltd
Glance View

Market Cap
14.4B EUR
Industry
Biotechnology

Roivant Sciences Ltd., founded in 2014 by entrepreneur Vivek Ramaswamy, emerged as a novel entity in the pharmaceutical industry by rethinking the drug development process. At the heart of Roivant’s strategy is its unique model of deploying a family of subsidiaries, each focused on developing a specific therapeutic area, referred to as “Vants.” These subsidiaries operate semi-independently, allowing for a nimble and focused approach to drug development while sharing centralized resources like regulatory expertise and funding strategies from Roivant itself. This decentralized yet coordinated structure aims to sidestep the traditional bottlenecks of large pharmaceutical companies, accelerating the time it takes to bring drugs from development to market. Roivant generates revenue by acquiring underdeveloped or previously shelved drug candidates from other pharmaceutical companies, then developing them through their Vants. Once these drugs have proved their potential through clinical trials, Roivant either licenses them out, partners with other companies for further development and commercialization, or sells a stake in the developed drug or entire Vant. This innovative approach allows them not only to mitigate risks associated with drug development but also to tap into a wide range of therapeutic areas, leveraging modern approaches like digital technology to optimize the drug development pipeline. Through this strategy, Roivant aims to capitalize on the inefficiencies in the pharmaceutical industry, delivering valuable medical solutions while generating substantial economic returns.

87S Intrinsic Value
7.86 EUR
Overvaluation 60%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-2 157.4%
=
Net Income
$-374m
/
Revenue
$20.3m
What is Roivant Sciences Ltd's current Net Margin?

The current Net Margin for Roivant Sciences Ltd is -2 157.4%, which is below its 3-year median of 1 419.2%.

How has Net Margin changed over time?

Over the last 3 years, Roivant Sciences Ltd’s Net Margin has increased from -2 290.8% to -2 157.4%. During this period, it reached a low of -3 092.2% on Dec 31, 2022 and a high of 14 350.4% on Mar 31, 2024.

Back to Top